ROGERIO DE SOUZA
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina - Líder
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina - Líder
121 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 121
- Unusual cause of wheezing: extrinsic bronchial compression by pulmonary artery aneurysm(2018) FERNANDES, Caio Julio Cesar; JASINOWODOLINSKI, Dany; SOUZA, Rogerio
- Clinical, demographic and functional evaluation of patients with hypersensitivity pneumonitis and their comparison based on current diagnostic criteria(2023) BRIDI, Guilherme Das Posses; SILVA, Bianca Freire Da; CUNHA, Marieta Cabral Amaral Da; QUEIROZ, Douglas Silva; ALVES- JR., Jose Leonidas; SALGE, Joao Marcos; CARVALHO, Celso R. F. De; KAIRALLA, Ronaldo Adib; SOUZA, Rogerio De; BALDI, Bruno Guedes
- Disfunção ventricular esquerda em pacientes com suspeita de hipertensão arterial pulmonar(2014) GAVILANES, Francisca; ALVES JR., Jose Leonidas; FERNANDES, Caio; PRADA, Luis Felipe Lopes; JARDIM, Carlos Viana Poyares; MORINAGA, Luciana Tamie Kato; DIAS, Bruno Arantes; HOETTE, Susana; SOUZA, RogerioObjective: To evaluate the role of right heart catheterization in the diagnosis of pulmonary arterial hypertension (PAH). Methods: We evaluated clinical, functional, and hemodynamic data from all patients who underwent right heart catheterization because of diagnostic suspicion of PAH-in the absence of severe left ventricular dysfunction (LVD), significant changes in pulmonary function tests, and ventilation/perfusion lung scintigraphy findings consistent with chronic pulmonary thromboembolism between 2008 and 2013 at our facility. Results: During the study period, 384 patients underwent diagnostic cardiac catheterization at our facility. Pulmonary hypertension (PH) was confirmed in 302 patients (78.6%). The mean age of those patients was 48.7 years. The patients without PH showed better hemodynamic profiles and lower levels of B-type natriuretic peptide. Nevertheless, 13.8% of the patients without PH were categorized as New York Heart Association functional class III or IV. Of the 218 patients who met the inclusion criteria, 40 (18.3% and 178 (81.7%) were diagnosed with PH associated with LVD (PH-LVD) and with PAH, respectively. The patients in the HP-LVD group were significantly older than were those in the PAH group (p < 0.0001). Conclusions: The proportional difference between the PAH and PH-LVD groups was quite significant, considering the absence of echocardiographic signs suggestive of severe LVD during the pre-catheterization investigation. Our results highlight the fundamental role of cardiac catheterization in the diagnosis of PAH, especially in older patients, in whom the prevalence of LVD that has gone undiagnosed by non-invasive tests is particularly relevant.
- Momentum(2017) SOUZA, Rogerio
- Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension(2015) MCLAUGHLIN, Vallerie; CHANNICK, Richard N.; GHOFRANI, Hossein-Ardeschir; LEMARIE, Jean-Christophe; NAEIJE, Robert; PACKER, Milton; SOUZA, Rogerio; TAPSON, Victor F.; TOLSON, Jonathan; HITI, Hikmet Al; MEYER, Gisela; HOEPER, Marius M.The safety and efficacy of adding bosentan to sildenafil in pulmonary arterial hypertension (PAH) patients was investigated. In this prospective, double-blind, event-driven trial, symptomatic PAH patients receiving stable sildenafil (>= 20 mg three times daily) for >= 3 months were randomised (1: 1) to placebo or bosentan (125 mg twice daily). The composite primary end-point was the time to the first morbidity/mortality event, defined as all-cause death, hospitalisation for PAH worsening or intravenous prostanoid initiation, atrial septostomy, lung transplant, or PAH worsening. Secondary/exploratory end-points included change in 6-min walk distance and World Health Organization functional class at 16 weeks, change in N-terminal pro-brain natriuretic peptide (NT-proBNP) over time, and all-cause death. Overall, 334 PAH patients were randomised to placebo (n=175) or bosentan (n=159). A primary end-point event occurred in 51.4% of patients randomised to placebo and 42.8% to bosentan (hazard ratio 0.83, 97.31% CI 0.58-1.19; p=0.2508). The mean between-treatment difference in 6-min walk distance at 16 weeks was + 21.8 m (95% CI + 5.9-37.8 m; p=0.0106). Except for NT-proBNP, no difference was observed for any other end-point. The safety profile of bosentan added to sildenafil was consistent with the known bosentan safety profile. In COMPASS-2, adding bosentan to stable sildenafil therapy was not superior to sildenafil monotherapy in delaying the time to the first morbidity/mortality event.
conferenceObject Impact of macitentan on the health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH): Results from a long-term randomised controlled trial(2013) JANSA, Pavel; CHANNICK, Richard; DELCROIX, Marion; GALIE, Nazzareno; GHOFRANI, Hossein-Ardeschir; HUNCHE, Elke; MEHTA, Sanjay; MITTELHOLZER, Camilla; PULIDO, Tomas; SASTRY, B. K. S.; SITBON, Olivier; SOUZA, Rogerio; TORBICKI, Adam; SIMONNEAU, Gerald; RUBIN, Lewis- Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats(2014) POLONIO, Igor Bastos; ACENCIO, Milena Marques Pagliareli; PAZETTI, Rogerio; ALMEIDA, Francine Maria de; SILVA, Brbara Soares da; PEREIRA, Karina Aparecida Bonifacio; SOUZA, RogerioWe assessed the effects of Iodenafil on hemodynamics and inflammation in the rat model of monocrotaline-induced pulmonary hypertension (PH). Thirty male Sprague-Dawley rats were randomly divided into three groups: control; monocrotaline (experimental model); and Iodenafila (experimental model followed by Iodenafil treatment, p.o., 5 mg/kg daily for 28 days) Mean pulmonary artery pressure (mPAP) was obtained by right heart catheterization. We investigated right ventricular hypertrophy (RVH) and IL-1 levels in lung fragments. The number of cases of RVH was significantly higher in the monocrotaline group than in the Iodenafil and control groups, as were mPAP and IL-1 levels. We conclude that Iodenafil can prevent monocrotaline-induced PH, RVH, and inflammation.
- JPB and the bibliometric indices(2017) SOUZA, Rogerio
- Do Parameters of Cardiac Function Predict Long-term Outcomes in Patients With Pulmonary Arterial Hypertension? Data From SERAPHIN, a Randomized Controlled Study of Macitentan(2013) CHANNICK, Richard; DELCROIX, Marion; GALIE, Nazzareno; GHOFRANI, Hossein A.; JANSA, Pavel; BRUN, Franck-Olivier Le; MEHTA, Sanjay; PERCHENET, Loic; PULIDO, Tomas; SASTRY, B. K.; SITBON, Olivier; SOUZA, Rogerio; TORBICKI, Adam; RUBIN, Lewis J.; SIMONNEAU, Gerald
- Schistosomiasis and pulmonary hypertension(2011) DOS, Caio Julio Cesar; FERNANDES, Santos; JARDIM, Carlos Viana Poyares; HOVNANIAN, Andre; HOETTE, Susana; MORINAGA, Luciana Kato; SOUZA, RogerioExpert Rev. Respir. Med. 5(5), 675-681 (2011) Schistosomiasis is one of the most prevalent chronic infectious diseases in the world. One of its most severe complications, pulmonary hypertension, occurs in up to 5% of patients with hepatosplenic schistosomiasis. The prevalence of schistosomiasis is so overwhelming that schistosomiasis-associated pulmonary hypertension (Sch-PH) may be the most prevalent cause of pulmonary hypertension around the world. Multiple pathways have been described as potential mechanisms of disease in Sch-PH, such as egg embolism, inflammatory disease or pulmonary blood overflow. The possible physiopathological mechanisms will be discussed in this article, as well the disease's clinical course and response to the treatment available.